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PURPOSE. To investigate phenotype characteristics of fellow eyes in patients with early onset of
neovascular age-related macular degeneration (NVAMD).
METHODS. Patients with new-onset unilateral NVAMD between 50 and 65 years (n ¼ 57, early-
onset choroidal neovascularization [CNV] group) or >80 years (n ¼ 47, late-onset CNV
group) or with nonneovascular AMD (n ¼ 98, no-CNV group) were included. Fellow eyes in
both CNV groups and the eyes with the more severe AMD staging in the no-CNV group were
used to evaluate number and size of macular drusen, extramacular drusen (EMD), pigmentary
abnormalities, and retinal pigment epithelium (RPE) atrophy on color photographs and
hyperreflective dots (HRD) and reticular pseudodrusen (RPD) on spectral-domain optical
coherence tomography (SDOCT) scans. Regression analysis was used to compare groups.
RESULTS. Occurrence of >20 macular drusen was more frequent in the early-onset CNV group
than the late-onset CNV group (odds ratio [OR] 2.93; P ¼ 0.01) or the no-CNV group (OR
2.17; P ¼ 0.02). Retinal pigment epithelium atrophy, RPD, and HRD appeared less frequently
in the early-onset CNV group than in the late-onset CNV group (RPE atrophy: OR 0.11; P ¼
0.005; RPD: OR 0.04; P ¼ 9.38 3 1010, HRD: OR 0.30; P ¼ 0.004) and no-CNV group (RPE
atrophy: OR 0.12; P ¼ 0.005; RPD: OR 0.40, P ¼ 0.03, HRD: not significant). No differences
were detected regarding presence of large drusen, pigmentary abnormalities, and EMD.
CONCLUSIONS. A large number of macular drusen in the fellow eye appeared to be characteristic
for early onset of NVAMD, whereas RPE atrophy, HRD, and RPD were more frequently present
in AMD patients > 80 years. Prospective trials with patients converting to NVAMD are
required to further analyze morphologic characteristics for early versus late development of
advanced AMD.
Keywords: neovascular age-related macular degeneration, fellow eye, spectral-domain optical
coherence tomography, reticular pseudodrusen
Before anti-VEGF agents became available, age-relatedmacular degeneration (AMD) was the leading cause of
severe visual loss in people aged 50 years or older in the
developed world.1 Multiple inherited and environmental
factors play a role in the development and severity of this
common disease.2 The incidence of typical AMD features,
including drusen and pigmentary abnormalities, choroidal
neovascularization (CNV), and geographic atrophy (GA),
increases with age.3,4 Not only the phenotype but also the
course of the disease varies strongly between individuals, with
some patients developing CNV early and some patients never
reaching this advanced stage of the disease. Once CNV
develops, eyes are at high risk for a severe decrease in visual
acuity.5
The reason for those intraindividual differences is not yet
fully understood. Smoking and genetic risk factors such as
polymorphisms in CFH and ARMS2 genes have been reported
to be associated with a higher risk for neovascular AMD.6,7
Morphologic risk factors for the development of advanced AMD
include large drusen, pigmentary abnormalities, and the
involvement of the fellow eye.4,8 Recently, genetic risk factors
for an early onset of CNV in AMD have been reported.9
However, morphologic parameters with a predictive value for
an early onset of CNV in AMD still need to be determined.
Despite the large intraindividual variability, studies have
reported a highly symmetrical appearance of both eyes of one
patient.10 Additionally, various studies have proposed that
patients with unilateral neovascular AMD have a substantial risk
of developing CNV in their fellow eye.8,11–15 Therefore, in eyes
with new-onset CNV, the morphologic appearance of the fellow
eye may reveal risk factors for development of CNV.
Phenotyping in large epidemiologic AMD trials was mostly
performed based on color fundus photographs. Since its first
description in 1991,16 optical coherence tomography (OCT)
has been widely adopted in clinical routine and is increasingly
used in clinical trials. The introduction of spectral-domain OCT
(SDOCT) allows evaluation of retinal and subretinal structures
with a potential influence on AMD development in high
resolution.17 Reticular pseudodrusen (RPD), detectable as
subretinal drusenoid deposits on SDOCT, are reported to be
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associated with the development of advanced AMD.18–23
Additionally, hyperreflective dots (HRD) are frequently present
in eyes with intermediate AMD or CNV and are presumed to
indicate imminent CNV activity or GA development.24–26
In this study, we aimed to identify possible markers for an
early or late onset of the advanced stage in AMD by analyzing
morphologic characteristics of the fellow eye in patients with
early onset of unilateral neovascular AMD (early-onset CNV
group) compared to AMD patients older than 80 years with
either new-onset unilateral CNV (late-onset CNV group) or
with nonneovascular AMD (no CNV group).
METHODS
Data Collection
For this retrospective study, the clinical database of the
Department of Ophthalmology at the University of Cologne
was screened for patients older than 50 years with neovascular
AMD. Clinical and imaging data of 527 consecutive patients
were reviewed. For inclusion in the study, patients were
required to have newly diagnosed unilateral CNV secondary to
AMD and color fundus photographs (FP), SDOCT volume
scans, and fluorescein angiography (FA) images available. Signs
for AMD had to be present in at least one eye. Patients between
50 and 65 years of age meeting the inclusion criteria were
included in the early-onset CNV group, and patients older than
80 years were included in the late-onset CNV group. Patients
between 66 and 79 years of age were excluded from this study.
Additionally, the European Genetic Database (EUGENDA,
www.eugenda.org [in the public domain]) was screened for
patients with available FPs and SDOCT scans, and all patients
with nonneovascular AMD and at least 80 years of age were
included in the no-CNV group. Further, two age-matched
comparator groups of 50 individuals each without AMD were
collected from the EUGENDA database (one group 50–65 years
of age and one group > 80 years of age).
For all patients, data collection included age, sex, and ocular
comorbidity. Patients with poor image quality or patients
demonstrating any other ophthalmic disease that may affect
grading were excluded from this study. Fundus photographs
were performed using the Canon Uvi fundus camera (Tokyo,
Japan) at the 408 setting. Fluorescein angiography and SDOCT
volume scans were performed using the Spectralis HRA and
SDOCT (Heidelberg Engineering, Heidelberg, Germany). This
research adhered to the tenets set forth in the Declaration of
Helsinki.
Image Assessment
Images were analyzed by two senior graders (TS and LS) of the
Cologne Image Reading Center (CIRCL) according to the
CIRCL standard grading protocol. Age-related macular degen-
eration staging was performed on FP for all cases. Early AMD
was defined as presence of at least 10 small drusen (<63-lm
diameter) combined with pigmentary abnormalities or at least
one intermediate-size drusen (63–124-lm diameter) within the
Early Treatment Diabetic Retinopathy Study (ETDRS) grid.
Intermediate AMD was defined as 1 to 15 intermediate drusen
or at least one large druse (‡125-lm diameter). Neovascular
AMD was considered present if CNV secondary to AMD was
detected, and GA was defined as atrophy of the retinal pigment
epithelium (RPE) larger than >175-lm diameter with involve-
ment of the central circle of the ETDRS grid.
The fellow eyes in the early-onset CNV group and in the
late-onset CNV group (eyes without CNV) and the eyes with
the higher AMD staging in the no-CNV group were used to
evaluate various morphologic features on FPs, including
presence of >20 drusen, presence of any large drusen, RPE
atrophy (sharply demarcated, depigmented area > 175-lm
diameter with increased visibility of choroidal vessels), or
pigmentary abnormalities (hypo- or hyperpigmentation other
than RPE atrophy) within the ETDRS grid and presence of >20
extramacular drusen (EMD, defined as drusen inside field 2 but
outside of the ETDRS grid). The SDOCT volume scans were
evaluated for the presence of HRD and RPD.
Statistical Analysis
Statistical analysis was performed using SPSS software version
21.0 (IBM Software and Systems, Armonk, NY, USA). Binary-
coded logistic regression was used to examine associations
between patient groups and grading features. Odds ratios (OR)
and 95% confidence intervals (CI) were computed, and P
values  0.05 were considered statistically significant.
RESULTS
Patient Characteristics
A total of 202 patients were included in our study. Fifty-seven
patients were included in the early-onset CNV group (mean
age, 61.41 6 3.77 years; range, 50–65 years), 47 patients in the
late-onset CNV group (mean age, 83.31 6 3.43 years; range,
80–95 years), and 98 patients in the no-CNV group (mean age,
86.81 6 5.13 years; range, 80–101 years). Eighty-seven patients
(43.1%) were male and 115 patients (56.9%) female.
Mean age of patients in the additional two age-matched
comparator groups without AMD was 62.00 6 2.09 years,
range, 58 to 65 (50 individuals), and 87.10 6 6.10 years, range,
80 to 97 years (50 individuals).
An overview about grading parameters and AMD staging is
given in Table 1.
Analysis of Morphologic Parameters
Fellow eyes in the early-onset CNV group showed significantly
more often >20 drusen within the ETDRS grid than fellow eyes
in the late-onset CNV group (OR 2.93, CI 1.31–6.58; P¼ 0.01)
or eyes in the no-CNV group (OR 2.17, CI 1.12–4.22; P¼ 0.02).
Appearance of large drusen and pigmentary abnormalities, as
well as EMD, showed no significant differences between
groups.
Retinal pigment epithelium atrophy was more frequently
present in the groups of patients > 80 years compared to the
early-onset CNV group (for the late-onset CNV group: OR 9.43,
CI 1.99–44.68; P ¼ 0.005; for the no-CNV group: OR 8.43, CI
1.91–37.28; P¼ 0.005). Presence of RPD was also significantly
higher in the groups of patients > 80 years compared to the
early-onset CNV group (for the late-onset CNV group: OR
26.86, CI 9.36–77.05; P¼ 9.383 1010, for the no-CNV group:
OR 2.50, CI 1.12–5.55; P¼ 0.03). In patients > 80 years, RPD
were more frequently present in the late-onset CNV group
compared to the no-CNV group (OR 10.76, CI 4.35–26.57; P¼
2.63 3 107).
Hyperreflective dots occurred more frequently in the late-
onset CNV group than in the early-onset CNV group (OR 3.32,
CI 1.48–7.46; P ¼ 0.004) or the no-CNV group (OR 2.93, CI
1.42–6.10; P ¼ 0.004).
A comparison between all groups regarding the various
morphologic parameters is presented in Table 2.
Differences between the early-onset CNV group (age 50–65
years) and the late-onset CNV and no-CNV groups (age > 80
years) may partially be a result of aging alone. To analyze this,
we compared two age-matched groups of individuals without
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AMD. Comparison between the comparator groups revealed
no statistically significant differences for all morphologic
parameters (Tables 1, 2). There was a trend (P ¼ 0.07) for
pigmentary abnormalities, indicating that these may be more
frequent in elderly people.
DISCUSSION
Prospective studies have demonstrated that large drusen and
pigmentary abnormalities are associated with an increased
risk for the development of CNV within 5 years.27,28
Additional morphologic parameters that have been reported
to be associated with advanced AMD include RPD and
HRD.18–20,22–26 Risk factors for CNV in the second eye include
drusen number and area as well as pigmentary abnormalities
within the macula.12 Early onset of the advanced stage of AMD
with development of CNV results in impairment of vision over
possibly many years and therefore severely impacts quality of
life. Epidemiologic studies revealed that past or current
smokers, homozygous carriers of the Y402H risk variant in
the ARMS2 gene, and patients carrying four risk alleles in CFH
and ARMS2 have a higher risk to show a more aggressive form
of the disease with development of CNV early in life.9
However, morphologic characteristics for patients with early
onset of CNV in AMD have not yet been fully understood.
In our study, >20 macular drusen appeared to be more
frequently present in fellow eyes of patients with early onset of
unilateral neovascular AMD and thus may represent an
indicator for a more aggressive course of the disease. Patients
> 80 years of age showed less frequently a large number of
macular drusen. There were no differences regarding drusen
number between AMD patients > 80 years with and without
CNV, suggesting that the number of drusen may have a lower
relevance for CNV occurrence in elderly patients. Silva et al.29
did not find a predictive value of drusen number or area,
presence of large drusen, or pigmentary changes for conver-
sion to wet AMD during a 3-year study follow-up.29 Fridberg et
al.30 reported that drusen area, as well as the presence of large
drusen or hyperpigmentation, is not a consistent risk factors
for an eye’s development of CNV.30 He proposed that whether
or not these features present relevant risk factors for CNV
development may depend on the location of the feature in
relation to the fovea. According to our results, we additionally
propose that the age of the patient may be another possibly
influencing factor.
In our study group we found no differences between
groups regarding the appearance of large drusen or pigmen-
tary abnormalities, indicating that these parameters do not
represent characteristic markers for an early or late onset of
CNV. Our study did not include analyses of follow-up images,
and thus was not designed to draw conclusions about the
predictive value of parameters. Therefore, large drusen or
pigmentary abnormalities may precede CNV development as
reported in the Age-Related Eye Disease Study; however, in our
study we did not detect differences between younger and older
patient groups.
Macular drusen have been reported to be associated with
peripheral drusen (Ersoy L, Schick T, De Graft D, et al.,
manuscript submitted, 2015).31 However, the relevance of
EMD for the development of AMD or CNV is not yet fully
understood. Previous studies indicated that EMD are not
associated with known AMD risk alleles (Ersoy L, Schick T, De
Graft D, et al., manuscript submitted, 2015), and thus patients
with drusen exclusively outside of the ETDRS grid may have
genetically the same risk to develop AMD compared to patients
without any drusen. In our study, we could not identify any
differences between groups regarding the occurrence of
drusen outside of the ETRDS grid, indicating that EMD do
not represent a characteristic marker of an early or late onset of
the neovascular stage in AMD.
Retinal pigment epithelium atrophy as well as RPD
appeared to be more frequently present in AMD patients over
80 years compared to patients with early onset of neovascular
AMD. Retinal pigment epithelium atrophy was more frequently
present in elderly patients, independently of whether they
showed CNV in one eye or not. Reticular pseudodrusen are
subretinal drusenoid deposits, accumulated above the RPE in
the subretinal space.22,23 In our study, RPD were more
frequently present in both elderly groups compared to the
early-onset CNV group, which supports the thesis that the risk
for RPD increases with age.32 Reticular pseudodrusen were
most strongly associated with the late-onset CNV group
compared to the no-CNV group, which is in agreement with
other studies indicating that RPD are associated with neovas-
cular AMD.20–22
Hyperreflective dots on SDOCT scans may correlate to
various features including hard exudates, hemorrhage, RPE
migration, or inflammatory cells.33 Schuman et al.34 studied the
association with drusen, supposing that HRD could be due to
the migration of macrophages that have gulped degenerative
material from damaged photoreceptors.34 Hyperreflective dots
TABLE 1. AMD Staging and Morphologic Parameters of Fellow Eyes (Early-Onset CNV and Late-Onset CNV Groups) and the Eyes With the More
Severe Staging (No-CNV Group)
AMD Staging/
Morphologic Parameters
Early-Onset
CNV Group,
n ¼ 57;
50–65 y
Age-Matched
Comparator
Group, n ¼ 50;
50–65 y
Late-Onset
CNV Group,
n ¼ 47;
>80 y
No-CNV
Group,
n ¼ 98;
>80 y
Age-Matched
Comparator
Group, n ¼ 50;
>80 y
Total for Early-
Onset, Late-Onset,
and No-CNV
Groups, n ¼ 202
No AMD 12, 21.1%* 50, 100% 3, 6.4%* 0, 0% 50, 100% 15, 7.4%
Early AMD 15, 26.3% 0, 0% 13, 27.7% 26, 26.5% 0, 0% 54, 26.7%
Intermediate AMD 30, 52.6% 0, 0% 26, 55.3% 54, 55.1% 0, 0% 110, 54.5%
Geographic atrophy 0, 0% 0, 0% 5, 10.6% 18, 18.4% 0, 0% 23, 11.4%
>20 macular drusen 33, 57.9% 0, 0% 15, 31.9% 38, 38.8% 0, 0% 86, 42.6%
Large drusen 30, 52.6% 0, 0% 30, 63.8% 66, 67.3% 0, 0% 126, 62.4%
Pigmentary abnormalities 23, 40.4% 1, 2% 26, 55.3% 45, 45.9% 6, 12% 94, 46.5%
RPE atrophy 2, 3.5% 0, 0% 12, 25.5% 23, 23.5% 0, 0% 37, 18.3%
>20 extramacular drusen 16, 28.1% 1, 2% 10, 21.3% 26, 26.5% 3, 6% 52, 25.7%
Hyperreflective dots 21, 36.8% 2, 4% 31, 66.0% 39, 39.8% 5, 10% 91, 45.0%
Reticular pseudodrusen 10, 17.5% 1, 2% 40, 85.1% 34, 34.7% 3, 6% 84, 41.6%
* All of these patients showed signs for AMD in the other eye.
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are reported to precede CNV development and to be
associated with CNV.25,35 This is in accordance with our
results, as HRD were more frequently detected in the late-onset
CNV group compared to the no-CNV group. This may be
explained by increased inflammatory cell migration processes
in patients with neovascular AMD. Hyperreflective dots
additionally occurred more often in the late-onset CNV group
than in the early-onset CNV group.
Our study is not without limitations, including its retro-
spective design and the relatively small number of patients per
group. Further, it cannot be ruled out that differences between
younger and older patient groups in our study may be a result
of aging rather than a result of early or late CNV development.
Comparison between age-matched comparator groups re-
vealed no differences regarding the presence of examined
morphologic parameters for individuals without AMD. In AMD
patients, however, drusen may regress over time, eventually
contributing to the development of RPE disturbance or
atrophy.36–38
However, our study also has several strengths. All images
were graded by trained reading center graders according to a
standard grading protocol. The utilization of high-resolution
SDOCT images allows a detailed interpretation of the complex
morphologic changes occurring in neovascular AMD, including
assessment of HRD, RPD, and CNV morphology.
In summary, a large number of macular drusen in the fellow
eye appeared to be characteristic in patients with early onset of
the neovascular stage in AMD, whereas HRD and RPD
appeared to be characteristic for elderly patients with
neovascular AMD. Retinal pigment epithelium atrophy has
been more frequently detected in older AMD patients
regardless of whether or not CNV was present. Prospective
studies with a large number of patients converting to
neovascular AMD are required to further identify morphologic
characteristics of patients with a more aggressive form of the
disease with early onset of CNV.
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